Literature DB >> 6133211

Possible teratogenicity of sulphasalazine.

N M Newman, J F Correy.   

Abstract

Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies. In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect. In the twin pregnancy, the mother had Crohn's disease. The first twin, a female, had a left Potter-type IIa polycystic kidney and a rudimentary left uterine cornu. The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus. Despite reports to the contrary, it is suggested that sulphasalazine may be teratogenic.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6133211     DOI: 10.5694/j.1326-5377.1983.tb136199.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  12 in total

1.  Renal anomalies in family members of infants with bilateral renal agenesis/adysplasia.

Authors:  Andrew L Schwaderer; Carlton M Bates; Kirk M McHugh; Kim L McBride
Journal:  Pediatr Nephrol       Date:  2006-09-15       Impact factor: 3.714

Review 2.  Fertility and pregnancy in the patient with inflammatory bowel disease.

Authors:  U Mahadevan
Journal:  Gut       Date:  2006-08       Impact factor: 23.059

Review 3.  Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?

Authors:  A A van Bodegraven; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

Review 4.  The management of rheumatic diseases in pregnancy.

Authors:  K Mitchell; M Kaul; Megan E B Clowse
Journal:  Scand J Rheumatol       Date:  2010-03       Impact factor: 3.641

Review 5.  Pregnancy related issues in inflammatory bowel disease: evidence base and patients' perspective.

Authors:  Christian P Selinger; Rupert Wl Leong; Simon Lal
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

Review 6.  Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy.

Authors:  W Connell; A Miller
Journal:  Drug Saf       Date:  1999-10       Impact factor: 5.606

Review 7.  Inflammatory bowel diseases and management considerations: fertility and pregnancy.

Authors:  Maria Moscandrew; Sunanda Kane
Journal:  Curr Gastroenterol Rep       Date:  2009-10

8.  Effects and treatment of inflammatory bowel disease during pregnancy.

Authors:  Harvinder Brar; Adrienne Einarson
Journal:  Can Fam Physician       Date:  2008-07       Impact factor: 3.275

9.  Maternal drug histories and central nervous system anomalies.

Authors:  K A Winship; D A Cahal; J C Weber; J P Griffin
Journal:  Arch Dis Child       Date:  1984-11       Impact factor: 3.791

Review 10.  Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data.

Authors:  Christina D Chambers; Zuhre N Tutuncu; Diana Johnson; Kenneth L Jones
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.